CN107148481A - 用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法 - Google Patents

用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法 Download PDF

Info

Publication number
CN107148481A
CN107148481A CN201580038260.0A CN201580038260A CN107148481A CN 107148481 A CN107148481 A CN 107148481A CN 201580038260 A CN201580038260 A CN 201580038260A CN 107148481 A CN107148481 A CN 107148481A
Authority
CN
China
Prior art keywords
braf
seq
mutation
inhibitor
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580038260.0A
Other languages
English (en)
Chinese (zh)
Inventor
M.P.莱韦斯克
R.杜默
D.维德默
M.I.G.拉伊吉马克斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107148481(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zurich Universität filed Critical Zurich Universität
Publication of CN107148481A publication Critical patent/CN107148481A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN201580038260.0A 2014-07-14 2015-07-13 用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法 Pending CN107148481A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176944.8 2014-07-14
EP14176944 2014-07-14
PCT/EP2015/065986 WO2016008853A1 (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Publications (1)

Publication Number Publication Date
CN107148481A true CN107148481A (zh) 2017-09-08

Family

ID=51210291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580038260.0A Pending CN107148481A (zh) 2014-07-14 2015-07-13 用于确定患有braf‑阳性癌症的患者为braf抑制剂非响应者且为mapk/erk抑制剂响应者的工具和方法

Country Status (7)

Country Link
US (1) US20190194757A1 (enExample)
EP (1) EP3169797B2 (enExample)
JP (1) JP7036594B2 (enExample)
CN (1) CN107148481A (enExample)
CA (1) CA2953732C (enExample)
ES (1) ES2751925T5 (enExample)
WO (1) WO2016008853A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111020033A (zh) * 2019-12-24 2020-04-17 中山大学达安基因股份有限公司 多重检测braf基因突变的试剂盒及方法
CN112795647A (zh) * 2019-11-14 2021-05-14 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
WO2018213302A1 (en) 2017-05-16 2018-11-22 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical braf mutations
US20240288397A1 (en) * 2021-06-23 2024-08-29 Royal Melbourne Institute Of Technology Conductometric sensor for detecting a nucleic acid and a method for the detection thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058532A2 (en) * 2010-10-28 2012-05-03 Yale University Methods and compositions for assessing and treating cancer
WO2012068562A2 (en) * 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
CN103402517A (zh) * 2010-11-19 2013-11-20 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法
US20140018372A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Crystalline form of a indolinone derivative and its use
US20140018405A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Anticancer Compounds
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3249053A1 (en) * 2009-03-27 2017-11-29 Life Technologies Corporation Methods, compositions, and kits for detecting allelic variants
WO2012061683A2 (en) 2010-11-05 2012-05-10 Glaxosmithkline Llc Methods for treating cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058532A2 (en) * 2010-10-28 2012-05-03 Yale University Methods and compositions for assessing and treating cancer
WO2012068562A2 (en) * 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
CN103402517A (zh) * 2010-11-19 2013-11-20 葛兰素史密斯克莱知识产权（第2号）有限公司 使用braf抑制剂的治疗方法
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
US20140018372A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Crystalline form of a indolinone derivative and its use
US20140018405A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Anticancer Compounds
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EMANUELA ROMANO等: "Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient With BRAFV600E-mutated Cutaneous Melanoma Successfully Rechallenged After Progression", 《CLIN CANCER RES》 *
JAMES G GREGER等: "Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations", 《MOL CANCER THER》 *
RAMIN NAZARIAN等: "Melanomas Acquire Resistance to B-RAF(V600E) Inhibition by RTK or N-RAS Upregulation", 《NATURE》 *
陈德高: "NRAS突变的黑色素瘤分子机制研究进展", 《科技视界》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112795647A (zh) * 2019-11-14 2021-05-14 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
CN111020033A (zh) * 2019-12-24 2020-04-17 中山大学达安基因股份有限公司 多重检测braf基因突变的试剂盒及方法

Also Published As

Publication number Publication date
WO2016008853A1 (en) 2016-01-21
EP3169797A1 (en) 2017-05-24
EP3169797B1 (en) 2019-08-21
EP3169797B2 (en) 2025-02-19
ES2751925T5 (en) 2025-05-13
CA2953732C (en) 2023-09-26
US20190194757A1 (en) 2019-06-27
JP7036594B2 (ja) 2022-03-15
CA2953732A1 (en) 2016-01-21
JP2017529094A (ja) 2017-10-05
ES2751925T3 (es) 2020-04-02

Similar Documents

Publication Publication Date Title
Ling et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
Pan et al. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer
Carvalho et al. Lack of microRNA‐101 causes E‐cadherin functional deregulation through EZH2 up‐regulation in intestinal gastric cancer
Nalejska et al. Prognostic and predictive biomarkers: tools in personalized oncology
Miyanaga et al. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing
Liu et al. Mutant SF3B1 promotes AKT-and NF-κB–driven mammary tumorigenesis
US9441277B2 (en) Compositions and methods for detecting cancer metastasis
JP6876680B2 (ja) ネオモルフィックｓｆ３ｂ１変異体に関連するスプライスバリアント
EP2650682A1 (en) Method for the prognosis and treatment of cancer metastasis
CN105980576B (zh) 用于源自乳腺癌的骨转移癌的预后和治疗的方法
Liu et al. Rare deleterious germline variants and risk of lung cancer
Wu et al. Characterization of the pleural microenvironment niche and cancer transition using single-cell RNA sequencing in EGFR-mutated lung cancer
EP3169797B1 (en) Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor
US20210238696A1 (en) Biomarkers for the Identification of Prostate Cancer and Methods of Use
Tian et al. NOP2-mediated 5-methylcytosine modification of APOL1 messenger RNA activates PI3K-Akt and facilitates clear cell renal cell carcinoma progression
WO2014135655A1 (en) Compositions and methods for treating muscle-invasive bladder cancer
Suh et al. RNA expression of 6 genes from metastatic mucosal gastric cancer serves as the global prognostic marker for gastric cancer with functional validation: Genetics and Genomics
CN114502745A (zh) 利用脱氧核糖核酸甲基化突变的抗癌免疫治疗反应性预测方法
US10400285B2 (en) DDX43 as a biomarker of resistance to MEK1/2 inhibitors
EP3129477B1 (en) A novel isoform of anaplastic lymphoma kinase and its uses
US20230304102A1 (en) Biomarkers for predicting responsiveness to shp2 inhibitor therapy
US20230383360A1 (en) Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy
KR101766005B1 (ko) 폐암 환자의 생존기간 예측용 키트와 생존기간 예측을 위한 정보 제공 방법
KR101805977B1 (ko) 폐암 환자의 생존기간 예측용 키트와 생존기간 예측을 위한 정보 제공 방법
KR20240026431A (ko) 암의 진단, 전이 가능성 또는 예후 예측용 바이오 마커 및 이의 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination